|Packaging Size||28 TABLETS|
|Composition||SOFOSBUVIR 400MG & DACLATASVIR 60MG|
|Treatment||Hepatitis C virus infection (HCV)|
|Manufacturer||Natco Pharma Ltd|
Hepcinat Plus ( SOFOSBUVIR 400MG & DACLATASVIR 60MG ) is a product of a pharmaceutical company from India Natco Pharma Ltd. The composition of the drug includes 400 mg of sofosbuvir and 60 mg of daclatasvir. Hepcinat Plus is an innovative direct acting antiviral drug. The drug has received the approval of leading world experts and is considered one of the most effective medicines for the treatment of hepatitis C.
Composition and properties
Hepcinat Plus contains two active substances - Sofosbuvir (400 mg) and Daclatasvir (60 mg).
Sofosbuvir inhibits the NS5B polymerase, prevents the hepatitis C virus from multiplying. Daclatasvir slows down the activity of the NS5A enzyme, and prevents the penetration of hepatitis C virus into healthy cells and its spread throughout the body. The immune system at the same time begins to fight the disease and gradually slows down its development.